kneatlogo.jpg
Global Pharma Selects Kneat to Digitize Computer System Validation
October 08, 2024 17:04 ET | kneat.com, inc.
Another global pharmaceutical company selects Kneat to digitize its validation processes.
Transparency Market Research
Anti-Infective Drugs Market Size Will Grow at a CAGR of 4.0% by 2031 | Surging Demand for Antivirals are Boost Market Development - Transparency Market Research, Inc.
October 08, 2024 08:36 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 08, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global anti-infective...
Transparency Market Research
Antibody Production Market Expected to Reach USD 30.7 Billion by 2031, Growing at a CAGR of 7.8% from 2023 to 2031: Transparency Market Research, Inc.
October 08, 2024 07:35 ET | Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research Inc. -, Oct. 08, 2024 (GLOBE NEWSWIRE) -- As per the report published by Transparency Market Research, the global antibody...
Avextra Logo.png
Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial Using a Proprietary Cannabis-based Medicine for the Treatment of the Symptoms of Neurodegenerative Diseases
October 08, 2024 07:00 ET | Avextra AG
The Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for NEUROBIS; a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral...
RM Primary Logo - Humble.png
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
October 07, 2024 09:00 ET | Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Reports First Quarter of Fiscal 2025 Financial Results and Provides Corporate Update
October 04, 2024 07:30 ET | Lifecore Biomedical, Inc.
-- Recorded Revenues of $24.7 Million for Q1 Fiscal 2025 -- -- Signed Multiple New Business Agreements with New and Existing Customers -- -- More than Doubled Capacity with Installation of 5-Head...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Raises $24.3 Million in Private Placement of Common Stock
October 04, 2024 07:20 ET | Lifecore Biomedical, Inc.
CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced the closing...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical to Report Financial Results for First Quarter of Fiscal 2025 Prior to Market Open on October 4, 2024
October 03, 2024 16:05 ET | Lifecore Biomedical, Inc.
CHASKA, Minn., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Portrait-Logo.jpg
ProductLife Group (PLG) Acquires Nextep to Further Expand its Global Patient Access Capabilities
October 03, 2024 03:00 ET | Groupe Product Life
ProductLife Group (PLG is pleased to announce the acquisition of Nextep, a reputed French consultancy specialized in market access and public affairs.
Exciting Advances in
Exciting Advances in Ulcerative Colitis Treatments: Skyrizi Gains Early Momentum Following FDA Approval in June
October 01, 2024 10:51 ET | Spherix Global Insights
EXTON, PA, Oct. 01, 2024 (GLOBE NEWSWIRE) -- The past twelve months have been transformative for the rapidly evolving ulcerative colitis (UC) market, with a surge in advanced therapies receiving FDA...